The miR-197/CKS1B/STAT3 axis can drive tumor PD-L1 expression as a biomarker of this cascade, and miR-197 replacement therapy may be a potential treatment strategy for chemoresistant NSCLC [54]. The gene discussed is CD274; the disease is neoplasm.